Member Info for shandypants2

Muggins good post re cash but the cashburn does include paying back loans and increasing inventory significantly so i think as people have mentioned the c£3m operating cash burn is a better figure to use. I also think staffing levels were increased in H1 in anticipation of H2 increased orders so hopefully admin costs will not be increasing much in H2.

As YE £10m has been reiterated and H2 expected to significantly exceed H1 lets say £7m rev. If that generates a gross profit of say £4m then the EBITDA loss could be marginal.

Ideally GB needs to get DVRG EBITDA profitable in H2 to demonstrate he is on top of costs.

However, the figures today shows that the £10m placing was a necessity despite his comments , just as the one a few years ago was.

they will mortgage the new building recently purchased so cash at 30/6 will be lower than the current position - would have been nice is this was stated in today's RNS. Still a slight concern though

and costs growing at almost the same rate. Cash burn still a concern despite recent placing

https://www.bbc.co.uk/news/newsbeat-58507739

if Gfin is still under the radar esports certainly isn't.

a little disappointed with these figures to be honest. Revenue progress seems good, but costs are rising by more and cash is being burnt quite quickly.
Hopefully costs will be more stable for H2 and ARR will continue to increase, so the loss will narrow.

Could also do with a few big contracts landing - it appears most are small to medium size.

as of 6 or so weeks ago there were less than 20m warrants left - this was confirmed via Investor Relations. Trading volumes were quite high last few days so it looks like a figure is even lower now.

wow delayed trade for a cool £250k. Must be a purchase based on the price at the time of the deal, not when it was reported. All looking good

EA you really are sad, i feel sorry for you.

Keeping me honest and twisting your words!!! This was your quote on POLB on 12th Aug.

" Schroders put in £2.25m to help CF show faith and get the IPO away but have since reduced to a non-notifiable amount and may even be completely out, we don't know but then they no longer have to tell us."

As i pointed out 10 seconds of researching the daily trading volumes of POLB made it an impossibility that Schroders had sold out, and now we find out that they still own 4.5% of POLB. What a surprise.

I'm sorry if you've lost money on ORPH but please stick to the POLB board.

i wouldn't be surprised if we get a RNS next week prior to the presentations - it's CF's style.

Good to see the resident derampers have left the building recently, however, noticed one is now over on the POLB board. Unbelievable!!

another share i am in is POLX which is hoping for FDA approval in early October.
POLX operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The Company focuses on improving the level of pulmonary functional imaging, and specializing the use of polarised Xenon gas (129Xe) as an imaging agent to visualize ventilation, and gas exchange.

As the product is not FDA approved their revenues are minimal and it is loss marking and recently did a big fundraise. It's current value is over £180m and rising - twice the STX valuation.
Once FDA approval is achieved it can sell its imaging machine to hospitals and the need for polarised xenon gas means they have a recurring revenue stream too. It clearly has great potential but i'm struggling to understand the valuation against STX's.
I suppose it just shows the importance of sentiment when valuing future growth.
One day Rodders!!!

the link won't work but CEO interview is available via V o x market website.

Explains the logic of acquiring Siege GG and target for GDM in general.

Currently c15m users generating 15p each (so just over £2m p.a) short term target to get this up to 50m and 30p each (so nearer £15m rev p.a). Mentioned Epicstream daily rev has increased from £2k a day to £3k a day since acquisition too.

YE financials out in October - wonder if this will be timed to coincide with the warrants expiring on 20/10??

Let's hope you are right Dave.

This share is very frustrating but there are reasons for this - FDA approval was 2 years ago and a lack of progress over the next 18 months, European revenues are low and not growing as quickly as we would like, a heavily discounted fundraise etc.

However, now we are selling Accrufer directly in the US, the biggest market by far, this is potentially transformation. The 'potentially' is key here as we have no evidence that the transformation is actually occurring despite good supporting information - new US based CEO, new NEDS, 4 senior managers headhunted from a competitor etc.

So this will drift until some actual evidence is provided and this takes time - hopefully the start of this will be announced on or before the 23rd Sept.

However, the best thing is this company will be valued at c£1bn even if it only achieves 50% of revenues in the US at year 5.
Year 5 rev is estimated at $300m to $400m. If it does 'only' $150m that's c$100m profit. At a conservative 10 x PE that's a $1bn company. Add on Europe and China etc and that gets us to c£1bn.

agree - bought at 4.39 . Marked as a sell but definitely not

clearly an admin error - as it's not face to face covid is irrelevant

actually just re-read the RNS and Siege has already exceeded 2020 rev and profits in 2021 (after 8 months of year) so it is probably nearer 2 x rev rather than 4. Obviously with GFIN's know how i'd expect these profits to reach 6 figures pretty quickly

seems another astute acquisition, however, £400k for a company with £100k revs seems a little on the high side IMHO

Supposedly laser light does work for early and moderate hair loss and is also FDA approved.
I don't think you can claim the photos are faked although clearly light, positioning and styling can be used to enhance the impact.
IDP hasn't done anything with Growlase as they ran out of money and clearly any new product requires initial marketing spend.
When this was initially announced a few years ago i remember doing some research and there were quite a few alternative products on the market, often at a much higher price. Previously IDP had a hair loss product/brand (Leimo??) that was incorporated into Growlase so it wasn't really a new market for IDP. If it didn't work they would have known this years ago.
Previous CEO Haris Chaudhry was the guy who pushed life sciences - surprised we couldn't flog it to him - he's made over £5m out of IDP.

https://www.infrared-light-therapy.com/laser-caps-hair-growth/

what LFT is being used in schools today? I have heard it is a different one that only requires a nose swab , not the back of the throat.

Is this still innova??

Good RNS, but being pedantic a 300 to 1,200 tpa production is a 300% increase so it won't be 4 x revenue it will be 3.

so what about the oil shipped pre the payment agreement. We have shipped millions of barrels and have never received any monies although clearly KRG has sold this oil?
Do we write this off too??